Specialized Programs of Research Excellence (SPORE)

Specialized Programs of Research Excellence (SPORE)

In 1992, the NCI established the Specialized Programs of Research Excellence (SPORE). Each SPORE focuses on a specific organ site, such as breast or lung cancer, or on a group of highly related cancers, such as gastrointestinal cancers. SPOREs are designed to enable the rapid and efficient movement of basic scientific findings into clinical settings, as well as to determine the biological basis for observations made in individuals with cancer or in populations at risk for cancer. Total funding shown represents the SPORE program using relevant P50s, P20s, U54s, and co-funded grants external to NCI.

The Translational Research Program (TRP) is the home of the SPOREs, a cornerstone of NCI’s efforts to promote collaborative, interdisciplinary translational cancer research. SPORE grants involve both basic and clinical/applied scientists, and support projects that will result in new and diverse approaches to the prevention, early detection, diagnosis and treatment of human cancers. For more information on these SPORE grants and organ sites, please visit the Translational Research Program.

The NCI Funded Research Portfolio (NFRP) website contains additional information about the SPORE grants that have been funded by NCI. The NFRP provides access to various NCI budget reports that contain information about research funding according to specific research categories. For more detailed information on all SPORE grants, please visit the NCI Funded Research Portfolio.

This content originally appeared on The National Cancer Institute website.

The Latest From Karmanos Cancer Institute

News

Karmanos Researcher Recruiting LGBTQ+ Cancer Survivors, Caregivers for Focus Groups

The Barbara Ann Karmanos Cancer Institute is partnering with Wayne State University (WSU) School of Medicine, the University of Rochester, and the...

Read More

Cancer is No Match for Wife's Persistence

When John Deitering’s annual prostate specific antigen (PSA) came back elevated, his long-time family doctor referred him to a urologist to get hi...

Read More

Dr. George Yoo Named in Becker’s 2024 Chief Medical Officers to Know

George Yoo, M.D., FACS , chief medical officer (CMO) at Karmanos Cancer Hospital, was listed on Becker’s Hospital Review’s 2024 Chief Medical Offi...

Read More
News

WWJ | Genetic Counselor Available to Speak with at Screening Saves Lives Event on June 8

Listen Now

WWJ | Screening Saves Lives Event Gives Participants Opportunity to Talk to Genetic Counselor

Listen Now

WWJ | Spotlight on Generosity: Bob Marzolf

Listen Now